AnaptysBio (NASDAQ:ANAB) Upgraded at Wolfe Research

Wolfe Research upgraded shares of AnaptysBio (NASDAQ:ANAB) to a strong-buy rating in a research report released on Monday,Zacks.com reports.

Several other research analysts have also commented on the company. Truist Financial cut their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. UBS Group upped their target price on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Wedbush reaffirmed an “outperform” rating and issued a $40.00 target price on shares of AnaptysBio in a research note on Monday. Wells Fargo & Company cut their target price on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. Finally, Guggenheim cut their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and a consensus price target of $40.08.

AnaptysBio Trading Down 0.9 %

Shares of NASDAQ ANAB opened at $16.51 on Monday. AnaptysBio has a 12 month low of $12.51 and a 12 month high of $41.31. The firm has a market capitalization of $502.40 million and a price-to-earnings ratio of -2.72. The business has a 50-day moving average of $17.23 and a 200-day moving average of $26.89.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. On average, analysts predict that AnaptysBio will post -6.08 earnings per share for the current year.

Insider Buying and Selling at AnaptysBio

In related news, Director Ecor1 Capital, Llc acquired 6,646 shares of the stock in a transaction on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the transaction, the director now owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. This trade represents a 0.08 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its holdings in shares of AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 644 shares in the last quarter. Algert Global LLC raised its holdings in shares of AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after acquiring an additional 1,078 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of AnaptysBio by 3.8% during the fourth quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 1,111 shares in the last quarter. nVerses Capital LLC raised its holdings in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of AnaptysBio during the third quarter valued at approximately $49,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.